首页 > 最新文献

Archives of dermatology最新文献

英文 中文
A nodule on the upper eyelid-quiz case. 上眼睑的结节——测验病例。
Pub Date : 2012-12-01 DOI: 10.1001/archderm.148.12.1411-d
Ben A Esdaile, Robert Almeyda, Olivia Espinosa de Los Monteros, Richard Turner, Jonathan C Bowling
{"title":"A nodule on the upper eyelid-quiz case.","authors":"Ben A Esdaile, Robert Almeyda, Olivia Espinosa de Los Monteros, Richard Turner, Jonathan C Bowling","doi":"10.1001/archderm.148.12.1411-d","DOIUrl":"https://doi.org/10.1001/archderm.148.12.1411-d","url":null,"abstract":"","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1411-6"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archderm.148.12.1411-d","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31129436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The utility of a portable video player in wart removal. 便携式视频播放器在疣去除中的应用。
Pub Date : 2012-12-01 DOI: 10.1001/2013.jamadermatol.215
Divya Seshadri, Siddharth Sarkar
{"title":"The utility of a portable video player in wart removal.","authors":"Divya Seshadri, Siddharth Sarkar","doi":"10.1001/2013.jamadermatol.215","DOIUrl":"https://doi.org/10.1001/2013.jamadermatol.215","url":null,"abstract":"","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1425-6; author reply 1426-7"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamadermatol.215","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful treatment of recurrent idiopathic plantar eccrine hidradenitis with colchicine. 秋水仙碱成功治疗复发性特发性足底汗腺炎。
Pub Date : 2012-12-01 DOI: 10.1001/archdermatol.2012.2221
Helene Sophie Scheer, Jivko Kamarashev, Lisa Weibel
{"title":"Successful treatment of recurrent idiopathic plantar eccrine hidradenitis with colchicine.","authors":"Helene Sophie Scheer, Jivko Kamarashev, Lisa Weibel","doi":"10.1001/archdermatol.2012.2221","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.2221","url":null,"abstract":"","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1357-9"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.2221","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31129431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. 与多激酶抑制剂vandetanib相关的皮肤毒性效应的新光谱。
Pub Date : 2012-12-01 DOI: 10.1001/2013.jamadermatol.192
Damien Giacchero, Constanza Ramacciotti, Jean Philippe Arnault, Maryse Brassard, Eric Baudin, Laurent Maksimovic, Christine Mateus, Gorana Tomasic, Janine Wechsler, Martin Schlumberger, Caroline Robert
S kin manifestations are among the most frequent adverse effects of targeted therapies. Hyperkeratosis and hand-foot skin reaction are observed with most raf and vascular endothelial growth factor (VEGF) inhibitors, whereas folliculitis is a hallmark of epidermal growth factor receptor (EGFR) blocking agents. Vandetanib (Zactima, ZD6474; AstraZeneca) is a multikinase inhibitor that targets EGFR, VEGF receptors 1, 2, and 3 and the RET (rearranged during transfection) receptor.
{"title":"A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.","authors":"Damien Giacchero, Constanza Ramacciotti, Jean Philippe Arnault, Maryse Brassard, Eric Baudin, Laurent Maksimovic, Christine Mateus, Gorana Tomasic, Janine Wechsler, Martin Schlumberger, Caroline Robert","doi":"10.1001/2013.jamadermatol.192","DOIUrl":"https://doi.org/10.1001/2013.jamadermatol.192","url":null,"abstract":"S kin manifestations are among the most frequent adverse effects of targeted therapies. Hyperkeratosis and hand-foot skin reaction are observed with most raf and vascular endothelial growth factor (VEGF) inhibitors, whereas folliculitis is a hallmark of epidermal growth factor receptor (EGFR) blocking agents. Vandetanib (Zactima, ZD6474; AstraZeneca) is a multikinase inhibitor that targets EGFR, VEGF receptors 1, 2, and 3 and the RET (rearranged during transfection) receptor.","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1418-20"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamadermatol.192","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 45
A variant of AESOP syndrome (adenopathy and extensive skin patch overlying a plasmacytoma) in a malignant blue-cell tumor. 恶性蓝细胞瘤AESOP综合征的一种变体(腺病和浆细胞瘤上广泛的皮肤斑块)。
Pub Date : 2012-12-01 DOI: 10.1001/archdermatol.2012.2858
Chong Wee Foo, Scott R Florell, Marta J Petersen
2006;332(6):339-345. 3. Weedon D. Weedon’s Skin Pathology. 3rd ed. Philadelphia, PA: Churchill Livingston; 2010. 4. Hassan Z, Mullins RF, Friedman BC, Shaver JR, Alam B, Mian MA. Purpura fulminans: a case series managed at a regional burn center. J Burn Care Res. 2008;29(2):411-415. 5. Darmstadt GL. Acute infectious purpura fulminans: pathogenesis and medical management. Pediatr Dermatol. 1998;15(3):169-183.
{"title":"A variant of AESOP syndrome (adenopathy and extensive skin patch overlying a plasmacytoma) in a malignant blue-cell tumor.","authors":"Chong Wee Foo, Scott R Florell, Marta J Petersen","doi":"10.1001/archdermatol.2012.2858","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.2858","url":null,"abstract":"2006;332(6):339-345. 3. Weedon D. Weedon’s Skin Pathology. 3rd ed. Philadelphia, PA: Churchill Livingston; 2010. 4. Hassan Z, Mullins RF, Friedman BC, Shaver JR, Alam B, Mian MA. Purpura fulminans: a case series managed at a regional burn center. J Burn Care Res. 2008;29(2):411-415. 5. Darmstadt GL. Acute infectious purpura fulminans: pathogenesis and medical management. Pediatr Dermatol. 1998;15(3):169-183.","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1431-2"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.2858","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Clinical and sociodemographic characteristics associated with thick melanomas. A population-based, case-case study in France. 与厚黑色素瘤相关的临床和社会人口学特征。在法国进行的以人群为基础的个案研究。
Pub Date : 2012-12-01 DOI: 10.1001/archdermatol.2012.2937
Florent Grange, Coralie Barbe, Francois Aubin, Dan Lipsker, Florence Granel-Brocard, Michel Velten, Sophie Dalac, François Truchetet, Catherine Michel, Audrey Mitschler, Gwendoline Arnoult, Antoine Buemi, Stéphane Dalle, Philippe Bernard, Anne-Sophie Woronoff

Objective: To identify clinical and sociodemographic factors associated with very thick melanoma (VTM) (Breslow thickness, 3 mm) in France.

Design: Retrospective, population-based, case-case study using a survey of cancer registries and questionnaires to practitioners.

Setting: Five regions covering 19.2% of the French territory and 8.2 million inhabitants.

Cases: Cases included all incident melanomas with a Breslow thickness of 3 mm or greater (ie, VTM), diagnosed between January 1 and December 31, 2008, in residents of the study area (Alsace, Bourgogne, Champagne-Ardenne, Franche-Comte', and Lorraine, France), and a randomly selected sample of melanomas thinner than 3 mm.

Main outcome measures: Circumstances of diagnosis,clinical and pathological characteristics of melanomas,and sociodemographic characteristics of patients(age, sex, residence, home and family life conditions, educational level, and smoking habits).

Results: Among 898 melanomas, 149 (16.6%) were VTMs. Very thick melanomas were more often diagnosed in a general-practice setting than thinner melanomas.The rate of immediate clinical recognition by dermatologists was lower for VTMs than for thinner melanomas. In a multivariate logistic regression analysis,factors associated with VTM were the nodular and acrolentiginous types; the head and neck and lower limb locations; older age; male sex; and being single, separated,divorced, or widowed. When only factors related to patients were taken into account, older age, male sex,and living alone were independent risk factors for VTM.The most significant risk was observed for patients living alone.

Conclusions: Intrinsic factors related to the tumor and socio demographic characteristics of patients contribute to the occurrence of VTM. These factors should be better targeted in future secondary prevention programs.

目的:确定与法国非常厚黑色素瘤(VTM) (Breslow厚度,3mm)相关的临床和社会人口学因素。设计:回顾性、以人群为基础的个案研究,采用癌症登记调查和从业人员问卷调查。环境:五个大区,占法国领土的19.2%,人口820万。病例:病例包括2008年1月1日至12月31日期间在研究区域(法国阿尔萨斯、勃艮第、香槟-阿登、弗朗什-孔特和洛林)居民中诊断出的布雷斯洛厚度为3毫米或以上的所有黑色素瘤(即VTM),以及随机选择的厚度小于3毫米的黑色素瘤样本。黑素瘤的诊断情况、临床病理特征及患者的社会人口学特征(年龄、性别、居住地、家庭及家庭生活条件、文化程度、吸烟习惯)。结果:898例黑色素瘤中,VTMs 149例,占16.6%。非常厚的黑色素瘤比薄的黑色素瘤更常被诊断出来。皮肤科医生对VTMs的即时临床识别率低于薄黑色素瘤。在多因素logistic回归分析中,与VTM相关的因素是结节型和渐尖性;头颈及下肢部位;老年;男性性;单身、分居、离婚或丧偶。当仅考虑与患者相关的因素时,年龄较大、男性和独居是VTM的独立危险因素。独居患者的风险最大。结论:与肿瘤相关的内在因素和患者的社会人口学特征是导致VTM发生的重要因素。这些因素应该在未来的二级预防规划中有更好的针对性。
{"title":"Clinical and sociodemographic characteristics associated with thick melanomas. A population-based, case-case study in France.","authors":"Florent Grange,&nbsp;Coralie Barbe,&nbsp;Francois Aubin,&nbsp;Dan Lipsker,&nbsp;Florence Granel-Brocard,&nbsp;Michel Velten,&nbsp;Sophie Dalac,&nbsp;François Truchetet,&nbsp;Catherine Michel,&nbsp;Audrey Mitschler,&nbsp;Gwendoline Arnoult,&nbsp;Antoine Buemi,&nbsp;Stéphane Dalle,&nbsp;Philippe Bernard,&nbsp;Anne-Sophie Woronoff","doi":"10.1001/archdermatol.2012.2937","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.2937","url":null,"abstract":"<p><strong>Objective: </strong>To identify clinical and sociodemographic factors associated with very thick melanoma (VTM) (Breslow thickness, 3 mm) in France.</p><p><strong>Design: </strong>Retrospective, population-based, case-case study using a survey of cancer registries and questionnaires to practitioners.</p><p><strong>Setting: </strong>Five regions covering 19.2% of the French territory and 8.2 million inhabitants.</p><p><strong>Cases: </strong>Cases included all incident melanomas with a Breslow thickness of 3 mm or greater (ie, VTM), diagnosed between January 1 and December 31, 2008, in residents of the study area (Alsace, Bourgogne, Champagne-Ardenne, Franche-Comte', and Lorraine, France), and a randomly selected sample of melanomas thinner than 3 mm.</p><p><strong>Main outcome measures: </strong>Circumstances of diagnosis,clinical and pathological characteristics of melanomas,and sociodemographic characteristics of patients(age, sex, residence, home and family life conditions, educational level, and smoking habits).</p><p><strong>Results: </strong>Among 898 melanomas, 149 (16.6%) were VTMs. Very thick melanomas were more often diagnosed in a general-practice setting than thinner melanomas.The rate of immediate clinical recognition by dermatologists was lower for VTMs than for thinner melanomas. In a multivariate logistic regression analysis,factors associated with VTM were the nodular and acrolentiginous types; the head and neck and lower limb locations; older age; male sex; and being single, separated,divorced, or widowed. When only factors related to patients were taken into account, older age, male sex,and living alone were independent risk factors for VTM.The most significant risk was observed for patients living alone.</p><p><strong>Conclusions: </strong>Intrinsic factors related to the tumor and socio demographic characteristics of patients contribute to the occurrence of VTM. These factors should be better targeted in future secondary prevention programs.</p>","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1370-6"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.2937","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30913827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 29
Gefitinib-induced paronychia: response to autologous platelet-rich plasma. 吉非替尼诱导甲亢:对自体富血小板血浆的反应。
Pub Date : 2012-12-01 DOI: 10.1001/archdermatol.2012.3022
Soon-Hyo Kwon, Jae-Woo Choi, Jong-Soo Hong, Sang-Young Byun, Kyoung-Chan Park, Sang-Woong Youn, Chang-Hun Huh, Jung-Im Na

Background: Paronychia has been reported in as many as 10% of patients treated with gefitinib. Although conservative management and treatment with topical or systemic antibiotics are beneficial, no effective method exists for intractable cases. Platelet-rich plasma (PRP)consists of a high concentration of platelets that promote wound healing through chemotaxis, cell proliferation,angiogenesis, and tissue remodeling.

Observations: We herein report a refractory case of gefitinib-induced paronychia successfully treated with autologous PRP. A 68-year-old woman who had been diagnosed as having lung adenocarcinoma with multiple bone and brain metastases initiated gefitinib therapy at an oral dose of 250 mg/d. After 1 month, multiple paronychia with periungual granulation appeared on the nailfold of the first, second, and third toenails of both feet.Because the paronychia recurred repeatedly despite use of a topical antibiotic, topical corticosteroid, and short term systemic antibiotic, she started PRP treatment. After 3 months, the lesion showed marked improvement with minimal pain or discharge.

Conclusion: This case highlights the therapeutic challenges of using PRP to promote tissue repair in intractable gefitinib-induced paronychia and merits further investigation.

背景:据报道,在接受吉非替尼治疗的患者中,有多达10%的患者出现甲沟炎。虽然保守管理和局部或全身抗生素治疗是有益的,但对于难治性病例没有有效的方法。富血小板血浆(PRP)由高浓度的血小板组成,通过趋化性、细胞增殖、血管生成和组织重塑促进伤口愈合。观察:我们在此报告一例难治性吉非替尼诱导的甲沟炎成功地用自体PRP治疗。一名68岁的妇女被诊断患有肺腺癌并多发性骨和脑转移,开始口服剂量为250mg /d的吉非替尼治疗。1个月后,双足1、2、3趾甲甲襞出现多发甲沟炎伴甲周肉芽肿。尽管使用了局部抗生素、局部皮质类固醇和短期全身抗生素,但甲沟炎反复复发,她开始了PRP治疗。3个月后,病变明显改善,疼痛或分泌物减少。结论:本病例强调了应用PRP促进难治性吉非替尼所致甲沟炎组织修复的治疗挑战,值得进一步研究。
{"title":"Gefitinib-induced paronychia: response to autologous platelet-rich plasma.","authors":"Soon-Hyo Kwon,&nbsp;Jae-Woo Choi,&nbsp;Jong-Soo Hong,&nbsp;Sang-Young Byun,&nbsp;Kyoung-Chan Park,&nbsp;Sang-Woong Youn,&nbsp;Chang-Hun Huh,&nbsp;Jung-Im Na","doi":"10.1001/archdermatol.2012.3022","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.3022","url":null,"abstract":"<p><strong>Background: </strong>Paronychia has been reported in as many as 10% of patients treated with gefitinib. Although conservative management and treatment with topical or systemic antibiotics are beneficial, no effective method exists for intractable cases. Platelet-rich plasma (PRP)consists of a high concentration of platelets that promote wound healing through chemotaxis, cell proliferation,angiogenesis, and tissue remodeling.</p><p><strong>Observations: </strong>We herein report a refractory case of gefitinib-induced paronychia successfully treated with autologous PRP. A 68-year-old woman who had been diagnosed as having lung adenocarcinoma with multiple bone and brain metastases initiated gefitinib therapy at an oral dose of 250 mg/d. After 1 month, multiple paronychia with periungual granulation appeared on the nailfold of the first, second, and third toenails of both feet.Because the paronychia recurred repeatedly despite use of a topical antibiotic, topical corticosteroid, and short term systemic antibiotic, she started PRP treatment. After 3 months, the lesion showed marked improvement with minimal pain or discharge.</p><p><strong>Conclusion: </strong>This case highlights the therapeutic challenges of using PRP to promote tissue repair in intractable gefitinib-induced paronychia and merits further investigation.</p>","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1399-402"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.3022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30913841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Removal of tattoos by q-switched laser: variables influencing outcome and sequelae in a large cohort of treated patients. q开关激光去除纹身:影响治疗患者预后和后遗症的变量。
Pub Date : 2012-12-01 DOI: 10.1001/archdermatol.2012.2946
Pier Luca Bencini, Simone Cazzaniga, Athanasia Tourlaki, Michela Gianna Galimberti, Luigi Naldi

OBJECTIVE To analyze variables affecting the treatment course and prognosis of Q-switched laser tattoo removal. DESIGN Observational prospective cohort study. SETTING The study was carried out in a referral center for surgery and laser surgery in Milan. PARTICIPANTS Of 397 consecutive patients initially enrolled from January 1, 1995, to December 31, 2010, 352 patients (201 men and 151 women; median age, 30 years) were included in the analysis. INTERVENTION All patients were treated by the same investigator with Q-switched 1064/532-nm Nd:YAG laser and Q-switched 755-nm alexandrite laser according to tattoo colors. Laser sessions were scheduled at 6-week or longer intervals. MAIN OUTCOME MEASURES Successful therapy was defined as removal of the tattoo, with no adverse effects other than transient hypochromia or darkening. RESULTS The cumulative rates of patients with successful tattoo removal were 47.2% (95% CI, 41.8%-52.5%) after 10 sessions and 74.8% (95% CI, 68.9%-80.7%) after 15 sessions. Smoking, the presence of colors other than black and red, a tattoo larger than 30 cm2, a tattoo located on the feet or legs or older than 36 months, high color density, treatment intervals of 8 weeks or less, and development of a darkening phenomenon were associated with a reduced clinical response to treatment. CONCLUSIONS To our knowledge, this study is the first to formally assess prognostic factors for effective tattoo removal by Q-switched laser. Several variables influence response rates and should be considered when planning tattoo removal treatments.

目的分析影响调q激光纹身去除术治疗过程及预后的因素。设计观察性前瞻性队列研究。研究在米兰的一个外科和激光手术转诊中心进行。从1995年1月1日至2010年12月31日,397名连续入组的患者中,352名患者(201名男性和151名女性;中位年龄为30岁)纳入分析。所有患者均由同一研究者根据纹身颜色分别使用调q 1064/532 nm Nd:YAG激光和调q 755 nm翠绿宝石激光进行治疗。激光治疗每隔6周或更长时间进行一次。成功的治疗被定义为去除纹身,除了短暂的低色度或变暗外没有其他不良反应。结果10个疗程后患者成功去除纹身的累计率为47.2% (95% CI, 41.8% ~ 52.5%), 15个疗程后患者成功去除纹身的累计率为74.8% (95% CI, 68.9% ~ 80.7%)。吸烟、出现黑色和红色以外的颜色、纹身大于30平方厘米、纹身位于脚或腿上或超过36个月、颜色密度高、治疗间隔为8周或更短、出现变黑现象与临床治疗反应降低有关。据我们所知,这项研究首次正式评估了q开关激光有效去除纹身的预后因素。有几个变量会影响应答率,在计划纹身去除治疗时应考虑这些变量。
{"title":"Removal of tattoos by q-switched laser: variables influencing outcome and sequelae in a large cohort of treated patients.","authors":"Pier Luca Bencini,&nbsp;Simone Cazzaniga,&nbsp;Athanasia Tourlaki,&nbsp;Michela Gianna Galimberti,&nbsp;Luigi Naldi","doi":"10.1001/archdermatol.2012.2946","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.2946","url":null,"abstract":"<p><p>OBJECTIVE To analyze variables affecting the treatment course and prognosis of Q-switched laser tattoo removal. DESIGN Observational prospective cohort study. SETTING The study was carried out in a referral center for surgery and laser surgery in Milan. PARTICIPANTS Of 397 consecutive patients initially enrolled from January 1, 1995, to December 31, 2010, 352 patients (201 men and 151 women; median age, 30 years) were included in the analysis. INTERVENTION All patients were treated by the same investigator with Q-switched 1064/532-nm Nd:YAG laser and Q-switched 755-nm alexandrite laser according to tattoo colors. Laser sessions were scheduled at 6-week or longer intervals. MAIN OUTCOME MEASURES Successful therapy was defined as removal of the tattoo, with no adverse effects other than transient hypochromia or darkening. RESULTS The cumulative rates of patients with successful tattoo removal were 47.2% (95% CI, 41.8%-52.5%) after 10 sessions and 74.8% (95% CI, 68.9%-80.7%) after 15 sessions. Smoking, the presence of colors other than black and red, a tattoo larger than 30 cm2, a tattoo located on the feet or legs or older than 36 months, high color density, treatment intervals of 8 weeks or less, and development of a darkening phenomenon were associated with a reduced clinical response to treatment. CONCLUSIONS To our knowledge, this study is the first to formally assess prognostic factors for effective tattoo removal by Q-switched laser. Several variables influence response rates and should be considered when planning tattoo removal treatments.</p>","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1364-9"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.2946","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30913327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 39
Integrated positron-emission tomography and computed tomography manifestations of cutaneous T-cell lymphoma. 皮肤t细胞淋巴瘤的综合正电子发射断层扫描和计算机断层扫描表现。
Pub Date : 2012-12-01 DOI: 10.1001/archdermatol.2012.3198
Maria R Kamstrup, Robert Gniadecki, Lars Friberg
is highly suggestive of a UV-A–induced mechanism. Photosensitization is an adverse effect of many kinase inhibitors such as imatinib, sorafenib, and vemurafenib. Imatinib inhibits the adenosine triphosphate–dependent transporter ABCG2 resulting in intracellular porphyrin accumulation and phototoxic effects in vitro. Since vandetanib also inhibits the transporter activity of ABCG2, a similar porphyrin-induced mechanism might explain the similar effect. In a report of 2 cases, vandetanib-associated cutaneous pigmentation was preceded by photosensitization. In our more extensive experience, only half of the patients with cutaneous pigmentation had prior or concomitant skin photosensitization, making the hypothesis of post-photosensitization pigmentation less likely. In 3 patients, a multinucleated giant-cell granuloma was found in the dermis, which could result from a direct deposit of the drug in the skin. Vandetanib is being tested in the treatment of several types of cancers. In patients with medullary thyroid cancers, it has already demonstrated a significant efficacy, which led the US Food and Drug Administration and European Medicines Agency to label the drug for patients with advanced disease in 2011. Dermatologists should be aware of the spectrum of vandetanib toxic effects, and careful photoprotection should be used to facilitate compliance with treatment.
{"title":"Integrated positron-emission tomography and computed tomography manifestations of cutaneous T-cell lymphoma.","authors":"Maria R Kamstrup,&nbsp;Robert Gniadecki,&nbsp;Lars Friberg","doi":"10.1001/archdermatol.2012.3198","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.3198","url":null,"abstract":"is highly suggestive of a UV-A–induced mechanism. Photosensitization is an adverse effect of many kinase inhibitors such as imatinib, sorafenib, and vemurafenib. Imatinib inhibits the adenosine triphosphate–dependent transporter ABCG2 resulting in intracellular porphyrin accumulation and phototoxic effects in vitro. Since vandetanib also inhibits the transporter activity of ABCG2, a similar porphyrin-induced mechanism might explain the similar effect. In a report of 2 cases, vandetanib-associated cutaneous pigmentation was preceded by photosensitization. In our more extensive experience, only half of the patients with cutaneous pigmentation had prior or concomitant skin photosensitization, making the hypothesis of post-photosensitization pigmentation less likely. In 3 patients, a multinucleated giant-cell granuloma was found in the dermis, which could result from a direct deposit of the drug in the skin. Vandetanib is being tested in the treatment of several types of cancers. In patients with medullary thyroid cancers, it has already demonstrated a significant efficacy, which led the US Food and Drug Administration and European Medicines Agency to label the drug for patients with advanced disease in 2011. Dermatologists should be aware of the spectrum of vandetanib toxic effects, and careful photoprotection should be used to facilitate compliance with treatment.","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1420-2"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.3198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib. 用vemurafenib治疗的化脓性汗腺炎,爆发性黑素细胞痣和角化病,毛毛样疹。
Pub Date : 2012-12-01 DOI: 10.1001/2013.jamadermatol.23
Liqiao Ma, Arturo R Dominguez, George R Collins, Kevin F Kia, Clay J Cockerell
reportedusingcryotherapy, 5 wereportthiscasetoemphasizetheimportanceofrecognizingCAHandpursuingtreatmentowingtothepotentialforpremalignantchange.Furthermore,thesuccessofcryotherapysupportstheconcept that this condition may be due to an abnormal proliferation of keratinocytes. Presumably, cryotherapy may destroy the abnormal keratinocytes and allow for repopulation with normal epidermal cells, thereby eliminating the potential for malignant transformation in the future. This case demonstrates that cryotherapy is an efficacioustherapeuticoptionthatshouldbeconsideredforthe treatment of CAH. Furthermore it may eliminate the potential for progression to more serious cutaneous disease.
{"title":"Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.","authors":"Liqiao Ma,&nbsp;Arturo R Dominguez,&nbsp;George R Collins,&nbsp;Kevin F Kia,&nbsp;Clay J Cockerell","doi":"10.1001/2013.jamadermatol.23","DOIUrl":"https://doi.org/10.1001/2013.jamadermatol.23","url":null,"abstract":"reportedusingcryotherapy, 5 wereportthiscasetoemphasizetheimportanceofrecognizingCAHandpursuingtreatmentowingtothepotentialforpremalignantchange.Furthermore,thesuccessofcryotherapysupportstheconcept that this condition may be due to an abnormal proliferation of keratinocytes. Presumably, cryotherapy may destroy the abnormal keratinocytes and allow for repopulation with normal epidermal cells, thereby eliminating the potential for malignant transformation in the future. This case demonstrates that cryotherapy is an efficacioustherapeuticoptionthatshouldbeconsideredforthe treatment of CAH. Furthermore it may eliminate the potential for progression to more serious cutaneous disease.","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1428-9"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamadermatol.23","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
期刊
Archives of dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1